New Drug Lifyorli Reduces Risk of Death by 35% in Phase 3 Trial for Platinum-Resistant Ovarian Cancer

For decades, a diagnosis of platinum-resistant ovarian cancer has represented one of the most daunting hurdles in oncology. When the disease progresses within six months of completing platinum-based chemotherapy, the cancer cells have effectively learned to outsmart the body's primary chemical weapons. Patients facing this aggressive recurrence typically survive for only about a year, and their treatment options have historically been limited to highly toxic, marginally effective salvage therapies.[1]

That grim prognosis is now shifting. In a landmark development for gynecologic oncology, the U.S. Food and Drug Administration has approved a novel medication called Lifyorli (relacorilant) that fundamentally alters how chemotherapy interacts with resistant tumors.

Rather than introducing a new cellular poison, Lifyorli strips away the cancer's chemical armor. The drug reduces the risk of death by 35% when combined with standard chemotherapy, marking one of the most significant survival improvements in this patient population in over twenty years.[1]

The clinical evidence anchoring this shift comes from the pivotal Phase 3 ROSELLA trial, whose final overall survival data was recently presented at the 2026 Society of Gynecologic Oncology Annual Meeting and published in The Lancet.[1]

The trial enrolled 381 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. All participants had previously received one to three lines of systemic therapy, including the targeted drug bevacizumab.[1][2]

Patients were randomized to receive either the chemotherapy drug nab-paclitaxel alone, or nab-paclitaxel combined with oral Lifyorli. The results demonstrated a clear and immediate divergence in clinical outcomes.[1]

Patients receiving the combination therapy achieved a median overall survival of 16.0 months, compared to 11.9 months for those receiving chemotherapy alone. This 4.1-month absolute extension in median survival is considered a massive leap in a disease state where progress is usually measured in mere weeks.[1]

Furthermore, the combination yielded a 30% reduction in the risk of disease progression, with a median progression-free survival of 6.5 months versus 5.5 months in the control group. At the 18-month mark, 46% of patients in the combination group were still alive, compared to just 27% in the chemotherapy-only cohort.[1][2]

To understand why this combination works, researchers point to the role of cortisol, the body's primary stress hormone. In healthy tissue, cortisol helps regulate metabolism and immune responses. But in the microenvironment of a tumor, cortisol can be hijacked to protect malignant cells.[2][4]

When cortisol binds to glucocorticoid receptors on ovarian cancer cells, it actively suppresses apoptosis—the programmed cell death that chemotherapy is designed to trigger. Essentially, the stress hormone acts as a biological shield, allowing the cancer to survive the toxic onslaught of drugs like nab-paclitaxel.[2][4]

Lifyorli is a selective glucocorticoid receptor antagonist (SGRA). Taken as a pill the day before, the day of, and the day after a chemotherapy infusion, it competitively binds to these receptors, blocking cortisol from attaching. By neutralizing this anti-apoptotic shield, Lifyorli leaves the cancer cells fully vulnerable to the chemotherapy.[2]

Crucially, the addition of Lifyorli did not significantly increase the safety burden or toxicity profile compared to nab-paclitaxel alone. Patients avoided the compounding, debilitating side effects that often accompany multi-drug chemotherapy regimens, allowing them to maintain a higher quality of life during treatment.[1]

The approval of Lifyorli also bypasses a common hurdle in modern targeted therapies: biomarker testing. Unlike other recent approvals in the ovarian cancer space—such as the combination of Keytruda and Taxol, which requires tumors to test positive for the PD-L1 biomarker—Lifyorli requires no specific genetic or molecular signature for eligibility.

This universal applicability means a much broader swath of the platinum-resistant population can access the drug immediately. Recognizing this, the National Comprehensive Cancer Network (NCCN) swiftly updated its clinical practice guidelines to include the Lifyorli combination as a preferred regimen.[3]

Despite the profound optimism surrounding the ROSELLA data, transparent uncertainties remain. Lifyorli is not a cure for platinum-resistant disease; it is a life-extending intervention. Researchers are still investigating why some patients experience durable, long-term responses while others see their cancer progress after several months.[1][4]

The success of this mechanism of action has also ignited a new frontier in pharmacological research. If blocking cortisol can resensitize ovarian tumors to chemotherapy, the same principle might apply to other hard-to-treat solid tumors that exploit glucocorticoid pathways, potentially rewriting the rules of chemotherapy resistance across multiple disciplines.[4]